Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Nab-paclitaxel, and S-1 for Gastric Cancer with Peritoneal Metastasis
NCT05441254Phase 2Unknown
- Sponsor
- Xiamen University Zhongshan Hospital
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in gastric cancer (GC), sponsored by Xiamen University Zhongshan Hospital. Primary endpoint: Progression Free Survival at 24 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05441254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441254.